Targeting metastatic leiomyosarcoma by rapamycin plus gemcitabine: An intriguing clinical observation

  • Authors:
    • Ofer Merimsky
  • View Affiliations

  • Published online on: November 1, 2004     https://doi.org/10.3892/ijmm.14.5.931
  • Pages: 931-935
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The emerging anti-cancer approach is based on combining a ‘traditional’ cytotoxic drug with a ‘signaling’ blocking agent. Such combination, if designed and applied properly, may increase selectivity towards tumor cells. The use of such combinations requires smart planning and choice of the drugs to be combined, their proper dosing as well as correct sequence and schedule of application. The combination of the anti-metabolite gemcitabine and the mTOR blocker, rapamycin, has achieved an impressive response in a patient with metastatic leiomyosarcoma.

Related Articles

Journal Cover

November 2004
Volume 14 Issue 5

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Merimsky O: Targeting metastatic leiomyosarcoma by rapamycin plus gemcitabine: An intriguing clinical observation. Int J Mol Med 14: 931-935, 2004.
APA
Merimsky, O. (2004). Targeting metastatic leiomyosarcoma by rapamycin plus gemcitabine: An intriguing clinical observation. International Journal of Molecular Medicine, 14, 931-935. https://doi.org/10.3892/ijmm.14.5.931
MLA
Merimsky, O."Targeting metastatic leiomyosarcoma by rapamycin plus gemcitabine: An intriguing clinical observation". International Journal of Molecular Medicine 14.5 (2004): 931-935.
Chicago
Merimsky, O."Targeting metastatic leiomyosarcoma by rapamycin plus gemcitabine: An intriguing clinical observation". International Journal of Molecular Medicine 14, no. 5 (2004): 931-935. https://doi.org/10.3892/ijmm.14.5.931